FTC Has Put PBMs, PBM Rebates in its Hot Seat

June 17th 2022

A week after announcing a study of the PBM industry, the Federal Trade Commission announced yesterday that it was stepping up possible enforcement actions targeting the industry's rebate practices. Rebates to exclude lower costs from formularies may constitute commercial bribery under the Robinson-Patman Act, the commission said.

ACO Update: The Pathways to Success Program

June 17th 2022

The program implemented by the Trump administration is designed to put more Medicare Shared Savings Program ACOs into two-sided risk. An industry group has discouraged participation in the program.

Aduhelm: Great Expectations Fizzle

June 17th 2022

Dogged by controversy, the new Alzheimer’s drug has not fared well since its approval by the FDA a year ago.

Digital Therapeutics Emerge Into Uncertain Regulatory, Payment Landscape

June 16th 2022

Legislation that would establish benefit categories for digital therapeutics has been introduced in Congress.

AI Could Dramatically Change OSA Diagnosis, But Only If Key Barriers are Cleared

June 16th 2022

Technical and regulatory hurdles abound, but another challenge is finding enough providers who are comfortable and competent with artificial intelligence technology.